©2010 Baishideng Publishing Group Co.
World J Clin Oncol. Feb 10, 2011; 2(2): 80-93
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.80
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.80
Table 1 Single-targeted and multi-targeted inhibitors of cellular tyrosine kinases ABL, SRC and janus kinase family
| Inhibitor | Tyrosine kinase target | Neoplasm(s) targeted | Clinical status |
| Bcr-Abl inhibitors | |||
| Imatinib mesylate (STI571) | Bcr-Abl, Kit, PDGFRβ | CML, ALL, GISTs | Approved |
| Nilotinib (AMN107) | BcrAbl, Kit, PDGFRβ | CML, Pcp ALL, HS, SM | Approved |
| Tyrphostin AG1024 | Bcr-Abl, P-Akt | CML (refract to STI571) | Preclinical |
| ON012380 | Bcr-Abl | CML | Phase I |
| Tyrphostin AG957 | Bcr-Abl | CML | Preclinical |
| Adaphostin | Bcr-Abl | CML | Preclinical |
| NS-187 | Bcr-Abl, Lyn | CML, Pcp ALL | Preclinical |
| SRC family inhibitors | |||
| Dasatinib (BMS354825) | Bcr-Abl, SRC | Adult CML, Pcp ALL | Approved |
| SKI-606 | Bcr-Abl, SRC | Pcp leukemia, breast | Phase I/II |
| AZD0530 | Bcr-Abl, SRC | Solid tumors | Phase I |
| Lung, liver, colorectal | Phase II | ||
| TG100435 | SRC, Lyn, abl, yes, lck, EphB4 | Anti-cancer | Preclinical |
| PD166326 | Bcr-Abl, SRC, lyn | CML | Preclinical |
| PD180970 | Bcr-Abl, SRC, Kit | CML | Preclinical |
| AZM475271 | SRC | Pancreatic | Preclinical |
| CGP76030 | Bcr-Abl, SRC | CML, prost, bone met | Preclinical |
| PP1 | FYN, Lck, Kit, Bcr-Abl | CML | Preclinical |
| PP2 | SRC, Lck, Fyn, Hck | Colon | Preclinical |
| AP-23236 | SRC | Bone metastases | Preclinical |
| PD173955 + 56 | BA, Kit, csk, PDGFRβ, EGFR | CML | Preclinical |
| SU6656 | Scr, Fyn, Yes, Lyn | Lymphoma | Preclinical |
| CGP77675 | SRC | Bone | Preclinical |
| SU11333 + 36 | SRC | Breast, colon | Preclinical |
| JAK inhibitors | |||
| CP-690 550 | JAK3 | Immunogenic | Preclinical |
| AG-490 | JAK2/3, EGFR | Leukemia, glioma | Preclinical |
| WHI-P154 | JAK3, Hck, Syk | Neural precursor cells | Preclinical |
| WHI-P131 | JAK3 | Leukemia, GVHD | Preclinical |
| WP-1034 | JAK, Stat | AML | Preclinical |
| LFM-A13 | JAK2, BTK | Leukemia | Preclinical |
- Citation: Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J Clin Oncol 2011; 2(2): 80-93
- URL: https://www.wjgnet.com/2218-4333/full/v2/i2/80.htm
- DOI: https://dx.doi.org/10.5306/wjco.v2.i2.80